Report Content
Chapter 1 Methodology & Scope
1.1 Methodology
1.2 Market scope & definitions
1.3 Base estimates and calculations
1.3.1 North America
1.3.2 Europe
1.3.3 Asia Pacific
1.3.4 Latin America
1.3.5 MEA
1.4 Forecast calculations
1.5 Data validation
1.6 COVID-19 impact analysis at global level
1.7 Data sources
1.7.1 Secondary
1.7.1.1 Paid sources
1.7.1.2 Unpaid sources
1.7.2 Primary
Chapter 2 Executive Summary
2.1 Autoinjectors market industry 3600 synopsis, 2018 - 2032
2.1.1 Business trends
2.1.2 Type trends
2.1.3 Route of administration trends
2.1.4 Therapy trends
2.1.5 End-use trends
2.1.6 Regional trends
Chapter 3 Autoinjectors Industry Insights
3.1 Industry segmentation
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Growing demand for targeted therapies
3.2.1.2 Availability of generic autoinjectors globally
3.2.1.3 Increasing incidence of diabetes and anaphylaxis
3.2.1.4 Rising patient preference towards self-administration of medication
3.2.2 Industry pitfalls & challenges
3.2.2.1 Availability of alternative treatment options
3.2.2.2 High pricing of the autoinjectors
3.3 Growth potential analysis
3.3.1 By type
3.3.2 By route of administration
3.3.3 By therapy
3.3.4 By end-use
3.4 COVID- 19 impact analysis
3.5 Regulatory landscape
3.5.1 U.S.
3.5.2 Europe
3.6 Technology landscape
3.7 Industry eco-system
3.7.1 Current trends in the industry
3.7.2 Start-up scenario
3.8 Porter's analysis
3.9 PESTEL analysis
Chapter 4 Competitive landscape
4.1 Introduction
4.2 Company market share, 2021
4.3 Competitive analysis of major market players
4.4 Competitive positioning matrix
4.5 Strategic outlook matrix
Chapter 5 Autoinjectors Market, By Type
5.1 Key type trends
5.2 Disposable
5.2.1 Market estimates and forecast, 2018 - 2032 (USD Million)
5.3 Reusable
5.3.1 Market estimates and forecast, 2018 - 2032 (USD Million)
Chapter 6 Autoinjectors Market, By Route of Administration
6.1 Key route of administration trends
6.2 Subcutaneous
6.2.1 Market estimates and forecast, 2018 - 2032 (USD Million)
6.3 Intramuscular
6.3.1 Market estimates and forecast, 2018 - 2032 (USD Million)
Chapter 7 Autoinjectors Market, By Therapy
7.1 Key therapy trends
7.2 Rheumatoid arthritis
7.2.1 Market estimates and forecast, 2018 - 2032 (USD Million)
7.3 Multiple sclerosis
7.3.1 Market estimates and forecast, 2018 - 2032 (USD Million)
7.4 Anaphylaxis
7.4.1 Market estimates and forecast, 2018 - 2032 (USD Million)
7.5 Diabetes
7.5.1 Market estimates and forecast, 2018 - 2032 (USD Million)
7.6 Oncology
7.6.1 Market estimates and forecast, 2018 - 2032 (USD Million)
7.7 Asthma
7.7.1 Market estimates and forecast, 2018 - 2032 (USD Million)
7.8 Migraine
7.8.1 Market estimates and forecast, 2018 - 2032 (USD Million)
7.9 Hormone therapy
7.9.1 Market estimates and forecast, 2018 - 2032 (USD Million)
7.10 Others
7.10.1 Market estimates and forecast, 2018 - 2032 (USD Million)
Chapter 8 Autoinjectors Market, By End-use
8.1 Key end-use trends
8.2 Hospital & clinics
8.2.1 Market estimates and forecast, 2018 - 2032 (USD Million)
8.3 Homecare Settings
8.3.1 Market estimates and forecast, 2018 - 2032 (USD Million)
8.4 Others
8.4.1 Market estimates and forecast, 2018 - 2032 (USD Million)
Chapter 9 Autoinjectors Market, By Region
9.1 Key regional trends
9.2 North America
9.2.1 U.S.
9.2.2 Canada
9.3 Europe
9.3.1 Germany
9.3.2 UK
9.3.3 France
9.3.4 Spain
9.3.5 Italy
9.4 Asia Pacific
9.4.1 China
9.4.2 Japan
9.4.3 India
9.4.4 Australia
9.5 Latin America
9.5.1 Brazil
9.5.2 Mexico
9.5.3 Argentina
9.6 Middle East & Africa
9.6.1 South Africa
9.6.2 Saudi Arabia
Chapter 10 Company Profiles
10.1 AbbVie Inc.
10.2 Mylan
10.3 GlaxoSmithKline Plc.
10.4 Ypsomed
10.5 Amgen
10.6 Becton, Dickinson and company
10.7 Eli Lilly and Company
10.8 Johnson & Johnson
10.9 Teva pharmaceuticals
10.10 Antares Pharma
